Used in targeted cancer therapy, particularly for treating advanced melanoma. It works by inhibiting MEK, a key protein in the MAPK signaling pathway that drives tumor growth. Often combined with vemurafenib, a BRAF inhibitor, to enhance effectiveness in patients with BRAF V600 mutation-positive melanoma. This combination delays disease progression and improves survival outcomes. Also under investigation for use in other cancers with similar genetic mutations, such as non-small cell lung cancer and colorectal cancer. Administered orally, it offers a convenient treatment option within precision medicine approaches.